Takeda Pharmaceutical Company Limited (NYSE: TAK) Stock Competitors & Peer Comparison

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 60B. In comparison, TEVA has a market cap of 45.6B. Regarding current trading prices, TAK is priced at $18.86 on the NYSE, while TEVA trades at $39.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 13.56, whereas TEVA's P/E ratio is 13.38. In terms of profitability, TAK's ROE is +0.02%, compared to TEVA's ROE of +0.09%. Regarding short-term risk, TAK is less volatile compared to TEVA. This indicates lower risk in terms of short-term price fluctuations for TAK.Check TEVA's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 60B. In comparison, HLN has a market cap of 40.8B. Regarding current trading prices, TAK is priced at $18.86 on the NYSE, while HLN trades at $9.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 13.56, whereas HLN's P/E ratio is 18.94. In terms of profitability, TAK's ROE is +0.02%, compared to HLN's ROE of +0.17%. Regarding short-term risk, TAK is less volatile compared to HLN. This indicates lower risk in terms of short-term price fluctuations for TAK.Check HLN's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 60B. In comparison, ZTS has a market cap of 29.8B. Regarding current trading prices, TAK is priced at $18.86 on the NYSE, while ZTS trades at $71.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 13.56, whereas ZTS's P/E ratio is 10.80. In terms of profitability, TAK's ROE is +0.02%, compared to ZTS's ROE of +0.69%. Regarding short-term risk, TAK is less volatile compared to ZTS. This indicates lower risk in terms of short-term price fluctuations for TAK.Check ZTS's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 60B. In comparison, VTRS has a market cap of 20.8B. Regarding current trading prices, TAK is priced at $18.86 on the NYSE, while VTRS trades at $17.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 13.56, whereas VTRS's P/E ratio is 7.08. In terms of profitability, TAK's ROE is +0.02%, compared to VTRS's ROE of -0.03%. Regarding short-term risk, TAK is less volatile compared to VTRS. This indicates lower risk in terms of short-term price fluctuations for TAK.Check VTRS's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 60B. In comparison, ITCI has a market cap of 14B. Regarding current trading prices, TAK is priced at $18.86 on the NYSE, while ITCI trades at $131.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 13.56, whereas ITCI's P/E ratio is -180.64. In terms of profitability, TAK's ROE is +0.02%, compared to ITCI's ROE of -0.09%. Regarding short-term risk, TAK is more volatile compared to ITCI. This indicates higher risk in terms of short-term price fluctuations for TAK.Check ITCI's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 60B. In comparison, CTLT has a market cap of 11.5B. Regarding current trading prices, TAK is priced at $18.86 on the NYSE, while CTLT trades at $63.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 13.56, whereas CTLT's P/E ratio is -27.84. In terms of profitability, TAK's ROE is +0.02%, compared to CTLT's ROE of -0.25%. Regarding short-term risk, TAK is more volatile compared to CTLT. This indicates higher risk in terms of short-term price fluctuations for TAK.Check CTLT's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 60B. In comparison, ELAN has a market cap of 11.2B. Regarding current trading prices, TAK is priced at $18.86 on the NYSE, while ELAN trades at $22.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 13.56, whereas ELAN's P/E ratio is 21.07. In terms of profitability, TAK's ROE is +0.02%, compared to ELAN's ROE of -0.03%. Regarding short-term risk, TAK is less volatile compared to ELAN. This indicates lower risk in terms of short-term price fluctuations for TAK.Check ELAN's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 60B. In comparison, RDY has a market cap of 10.2B. Regarding current trading prices, TAK is priced at $18.86 on the NYSE, while RDY trades at $12.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 13.56, whereas RDY's P/E ratio is 20.09. In terms of profitability, TAK's ROE is +0.02%, compared to RDY's ROE of +0.09%. Regarding short-term risk, TAK is less volatile compared to RDY. This indicates lower risk in terms of short-term price fluctuations for TAK.Check RDY's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 60B. In comparison, ALKS has a market cap of 6.9B. Regarding current trading prices, TAK is priced at $18.86 on the NYSE, while ALKS trades at $40.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 13.56, whereas ALKS's P/E ratio is 43.00. In terms of profitability, TAK's ROE is +0.02%, compared to ALKS's ROE of +0.04%. Regarding short-term risk, TAK is less volatile compared to ALKS. This indicates lower risk in terms of short-term price fluctuations for TAK.Check ALKS's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 60B. In comparison, LNTH has a market cap of 6.5B. Regarding current trading prices, TAK is priced at $18.86 on the NYSE, while LNTH trades at $99.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 13.56, whereas LNTH's P/E ratio is 16.76. In terms of profitability, TAK's ROE is +0.02%, compared to LNTH's ROE of +0.23%. Regarding short-term risk, TAK is more volatile compared to LNTH. This indicates higher risk in terms of short-term price fluctuations for TAK.Check LNTH's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 60B. In comparison, AMRX has a market cap of 6.3B. Regarding current trading prices, TAK is priced at $18.86 on the NYSE, while AMRX trades at $19.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 13.56, whereas AMRX's P/E ratio is 21.97. In terms of profitability, TAK's ROE is +0.02%, compared to AMRX's ROE of -3.27%. Regarding short-term risk, TAK is less volatile compared to AMRX. This indicates lower risk in terms of short-term price fluctuations for TAK.Check AMRX's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 60B. In comparison, INDV has a market cap of 4.5B. Regarding current trading prices, TAK is priced at $18.86 on the NYSE, while INDV trades at $35.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 13.56, whereas INDV's P/E ratio is 9.81. In terms of profitability, TAK's ROE is +0.02%, compared to INDV's ROE of -2.16%. Regarding short-term risk, TAK is less volatile compared to INDV. This indicates lower risk in terms of short-term price fluctuations for TAK.Check INDV's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 60B. In comparison, RGC has a market cap of 3.1B. Regarding current trading prices, TAK is priced at $18.86 on the NYSE, while RGC trades at $6.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 13.56, whereas RGC's P/E ratio is -434.51. In terms of profitability, TAK's ROE is +0.02%, compared to RGC's ROE of -2.32%. Regarding short-term risk, TAK is less volatile compared to RGC. This indicates lower risk in terms of short-term price fluctuations for TAK.Check RGC's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 60B. In comparison, ALVOW has a market cap of 2.8B. Regarding current trading prices, TAK is priced at $18.86 on the NYSE, while ALVOW trades at $0.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 13.56, whereas ALVOW's P/E ratio is 43.76. In terms of profitability, TAK's ROE is +0.02%, compared to ALVOW's ROE of +0.77%. Regarding short-term risk, TAK is more volatile compared to ALVOW. This indicates higher risk in terms of short-term price fluctuations for TAK.Check ALVOW's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 60B. In comparison, SUPN has a market cap of 2.5B. Regarding current trading prices, TAK is priced at $18.86 on the NYSE, while SUPN trades at $42.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 13.56, whereas SUPN's P/E ratio is 13.94. In terms of profitability, TAK's ROE is +0.02%, compared to SUPN's ROE of -0.10%. Regarding short-term risk, TAK is less volatile compared to SUPN. This indicates lower risk in terms of short-term price fluctuations for TAK.Check SUPN's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 60B. In comparison, HCM has a market cap of 2.4B. Regarding current trading prices, TAK is priced at $18.86 on the NYSE, while HCM trades at $13.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 13.56, whereas HCM's P/E ratio is 5.22. In terms of profitability, TAK's ROE is +0.02%, compared to HCM's ROE of +0.01%. Regarding short-term risk, TAK is less volatile compared to HCM. This indicates lower risk in terms of short-term price fluctuations for TAK.Check HCM's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 60B. In comparison, DCPH has a market cap of 2.2B. Regarding current trading prices, TAK is priced at $18.86 on the NYSE, while DCPH trades at $25.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 13.56, whereas DCPH's P/E ratio is -11.58. In terms of profitability, TAK's ROE is +0.02%, compared to DCPH's ROE of -0.56%. Regarding short-term risk, TAK is more volatile compared to DCPH. This indicates higher risk in terms of short-term price fluctuations for TAK.Check DCPH's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 60B. In comparison, PRGO has a market cap of 2.1B. Regarding current trading prices, TAK is priced at $18.86 on the NYSE, while PRGO trades at $15.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 13.56, whereas PRGO's P/E ratio is 6.17. In terms of profitability, TAK's ROE is +0.02%, compared to PRGO's ROE of -0.56%. Regarding short-term risk, TAK is less volatile compared to PRGO. This indicates lower risk in terms of short-term price fluctuations for TAK.Check PRGO's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 60B. In comparison, BHC has a market cap of 2.1B. Regarding current trading prices, TAK is priced at $18.86 on the NYSE, while BHC trades at $5.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 13.56, whereas BHC's P/E ratio is 1.45. In terms of profitability, TAK's ROE is +0.02%, compared to BHC's ROE of +0.89%. Regarding short-term risk, TAK is less volatile compared to BHC. This indicates lower risk in terms of short-term price fluctuations for TAK.Check BHC's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 60B. In comparison, AVDL has a market cap of 2.1B. Regarding current trading prices, TAK is priced at $18.86 on the NYSE, while AVDL trades at $21.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 13.56, whereas AVDL's P/E ratio is -1082.00. In terms of profitability, TAK's ROE is +0.02%, compared to AVDL's ROE of +0.05%. Regarding short-term risk, TAK is more volatile compared to AVDL. This indicates higher risk in terms of short-term price fluctuations for TAK.Check AVDL's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 60B. In comparison, TRLV has a market cap of 2.1B. Regarding current trading prices, TAK is priced at $18.86 on the NYSE, while TRLV trades at $12.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 13.56, whereas TRLV's P/E ratio is -4.96. In terms of profitability, TAK's ROE is +0.02%, compared to TRLV's ROE of -0.44%. Regarding short-term risk, TAK is less volatile compared to TRLV. This indicates lower risk in terms of short-term price fluctuations for TAK.Check TRLV's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 60B. In comparison, ALVO has a market cap of 1.9B. Regarding current trading prices, TAK is priced at $18.86 on the NYSE, while ALVO trades at $5.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 13.56, whereas ALVO's P/E ratio is -9.75. In terms of profitability, TAK's ROE is +0.02%, compared to ALVO's ROE of +0.77%. Regarding short-term risk, TAK is less volatile compared to ALVO. This indicates lower risk in terms of short-term price fluctuations for TAK.Check ALVO's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 60B. In comparison, EMBCV has a market cap of 1.9B. Regarding current trading prices, TAK is priced at $18.86 on the NYSE, while EMBCV trades at $33.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 13.56, whereas EMBCV's P/E ratio is N/A. In terms of profitability, TAK's ROE is +0.02%, compared to EMBCV's ROE of -0.19%. Regarding short-term risk, TAK is less volatile compared to EMBCV. This indicates lower risk in terms of short-term price fluctuations for TAK.Check EMBCV's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 60B. In comparison, DVAX has a market cap of 1.8B. Regarding current trading prices, TAK is priced at $18.86 on the NYSE, while DVAX trades at $15.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 13.56, whereas DVAX's P/E ratio is -41.89. In terms of profitability, TAK's ROE is +0.02%, compared to DVAX's ROE of -0.10%. Regarding short-term risk, TAK is more volatile compared to DVAX. This indicates higher risk in terms of short-term price fluctuations for TAK.Check DVAX's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 60B. In comparison, ANIP has a market cap of 1.7B. Regarding current trading prices, TAK is priced at $18.86 on the NYSE, while ANIP trades at $74.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 13.56, whereas ANIP's P/E ratio is 9.00. In terms of profitability, TAK's ROE is +0.02%, compared to ANIP's ROE of +0.19%. Regarding short-term risk, TAK is less volatile compared to ANIP. This indicates lower risk in terms of short-term price fluctuations for TAK.Check ANIP's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 60B. In comparison, TARO has a market cap of 1.6B. Regarding current trading prices, TAK is priced at $18.86 on the NYSE, while TARO trades at $42.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 13.56, whereas TARO's P/E ratio is 30.05. In terms of profitability, TAK's ROE is +0.02%, compared to TARO's ROE of +0.03%. Regarding short-term risk, TAK is more volatile compared to TARO. This indicates higher risk in terms of short-term price fluctuations for TAK.Check TARO's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 60B. In comparison, ETON has a market cap of 1.6B. Regarding current trading prices, TAK is priced at $18.86 on the NYSE, while ETON trades at $57.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 13.56, whereas ETON's P/E ratio is 151.79. In terms of profitability, TAK's ROE is +0.02%, compared to ETON's ROE of +0.40%. Regarding short-term risk, TAK is less volatile compared to ETON. This indicates lower risk in terms of short-term price fluctuations for TAK.Check ETON's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 60B. In comparison, PAHC has a market cap of 1.4B. Regarding current trading prices, TAK is priced at $18.86 on the NYSE, while PAHC trades at $34.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 13.56, whereas PAHC's P/E ratio is 11.76. In terms of profitability, TAK's ROE is +0.02%, compared to PAHC's ROE of +0.29%. Regarding short-term risk, TAK is less volatile compared to PAHC. This indicates lower risk in terms of short-term price fluctuations for TAK.Check PAHC's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 60B. In comparison, CRON has a market cap of 1.2B. Regarding current trading prices, TAK is priced at $18.86 on the NYSE, while CRON trades at $3.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 13.56, whereas CRON's P/E ratio is 17.10. In terms of profitability, TAK's ROE is +0.02%, compared to CRON's ROE of +0.06%. Regarding short-term risk, TAK is less volatile compared to CRON. This indicates lower risk in terms of short-term price fluctuations for TAK.Check CRON's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 60B. In comparison, HROW has a market cap of 1.2B. Regarding current trading prices, TAK is priced at $18.86 on the NYSE, while HROW trades at $33.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 13.56, whereas HROW's P/E ratio is -33.40. In terms of profitability, TAK's ROE is +0.02%, compared to HROW's ROE of -1.04%. Regarding short-term risk, TAK is less volatile compared to HROW. This indicates lower risk in terms of short-term price fluctuations for TAK.Check HROW's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 60B. In comparison, AMPH has a market cap of 1.2B. Regarding current trading prices, TAK is priced at $18.86 on the NYSE, while AMPH trades at $26.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 13.56, whereas AMPH's P/E ratio is 8.92. In terms of profitability, TAK's ROE is +0.02%, compared to AMPH's ROE of +0.10%. Regarding short-term risk, TAK is less volatile compared to AMPH. This indicates lower risk in terms of short-term price fluctuations for TAK.Check AMPH's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 60B. In comparison, PCRX has a market cap of 988.1M. Regarding current trading prices, TAK is priced at $18.86 on the NYSE, while PCRX trades at $25.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 13.56, whereas PCRX's P/E ratio is 9.66. In terms of profitability, TAK's ROE is +0.02%, compared to PCRX's ROE of +0.02%. Regarding short-term risk, TAK is less volatile compared to PCRX. This indicates lower risk in terms of short-term price fluctuations for TAK.Check PCRX's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 60B. In comparison, PETQ has a market cap of 919.2M. Regarding current trading prices, TAK is priced at $18.86 on the NYSE, while PETQ trades at $30.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 13.56, whereas PETQ's P/E ratio is 83.73. In terms of profitability, TAK's ROE is +0.02%, compared to PETQ's ROE of +0.01%. Regarding short-term risk, TAK is more volatile compared to PETQ. This indicates higher risk in terms of short-term price fluctuations for TAK.Check PETQ's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 60B. In comparison, COLL has a market cap of 730.7M. Regarding current trading prices, TAK is priced at $18.86 on the NYSE, while COLL trades at $22.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 13.56, whereas COLL's P/E ratio is 2.83. In terms of profitability, TAK's ROE is +0.02%, compared to COLL's ROE of +0.16%. Regarding short-term risk, TAK is less volatile compared to COLL. This indicates lower risk in terms of short-term price fluctuations for TAK.Check COLL's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 60B. In comparison, IRWD has a market cap of 679.9M. Regarding current trading prices, TAK is priced at $18.86 on the NYSE, while IRWD trades at $4.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 13.56, whereas IRWD's P/E ratio is 5.29. In terms of profitability, TAK's ROE is +0.02%, compared to IRWD's ROE of -0.57%. Regarding short-term risk, TAK is less volatile compared to IRWD. This indicates lower risk in terms of short-term price fluctuations for TAK.Check IRWD's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 60B. In comparison, AQST has a market cap of 587.2M. Regarding current trading prices, TAK is priced at $18.86 on the NYSE, while AQST trades at $4.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 13.56, whereas AQST's P/E ratio is -7.20. In terms of profitability, TAK's ROE is +0.02%, compared to AQST's ROE of +2.44%. Regarding short-term risk, TAK is less volatile compared to AQST. This indicates lower risk in terms of short-term price fluctuations for TAK.Check AQST's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 60B. In comparison, BDSI has a market cap of 577.1M. Regarding current trading prices, TAK is priced at $18.86 on the NYSE, while BDSI trades at $5.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 13.56, whereas BDSI's P/E ratio is 6.82. In terms of profitability, TAK's ROE is +0.02%, compared to BDSI's ROE of +0.57%. Regarding short-term risk, TAK is more volatile compared to BDSI. This indicates higher risk in terms of short-term price fluctuations for TAK.Check BDSI's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 60B. In comparison, EVO has a market cap of 554.2M. Regarding current trading prices, TAK is priced at $18.86 on the NYSE, while EVO trades at $1.56.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 13.56, whereas EVO's P/E ratio is -2.20. In terms of profitability, TAK's ROE is +0.02%, compared to EVO's ROE of -0.27%. Regarding short-term risk, TAK is less volatile compared to EVO. This indicates lower risk in terms of short-term price fluctuations for TAK.Check EVO's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 60B. In comparison, GLAS has a market cap of 551.3M. Regarding current trading prices, TAK is priced at $18.86 on the NYSE, while GLAS trades at $6.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 13.56, whereas GLAS's P/E ratio is -12.72. In terms of profitability, TAK's ROE is +0.02%, compared to GLAS's ROE of -0.51%. Regarding short-term risk, TAK is less volatile compared to GLAS. This indicates lower risk in terms of short-term price fluctuations for TAK.Check GLAS's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 60B. In comparison, EOLS has a market cap of 524.9M. Regarding current trading prices, TAK is priced at $18.86 on the NYSE, while EOLS trades at $7.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 13.56, whereas EOLS's P/E ratio is -25.24. In terms of profitability, TAK's ROE is +0.02%, compared to EOLS's ROE of +1.23%. Regarding short-term risk, TAK is less volatile compared to EOLS. This indicates lower risk in terms of short-term price fluctuations for TAK.Check EOLS's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 60B. In comparison, KMDA has a market cap of 503.1M. Regarding current trading prices, TAK is priced at $18.86 on the NYSE, while KMDA trades at $8.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 13.56, whereas KMDA's P/E ratio is 22.95. In terms of profitability, TAK's ROE is +0.02%, compared to KMDA's ROE of +0.08%. Regarding short-term risk, TAK is less volatile compared to KMDA. This indicates lower risk in terms of short-term price fluctuations for TAK.Check KMDA's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 60B. In comparison, TKNO has a market cap of 500.2M. Regarding current trading prices, TAK is priced at $18.86 on the NYSE, while TKNO trades at $9.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 13.56, whereas TKNO's P/E ratio is -30.10. In terms of profitability, TAK's ROE is +0.02%, compared to TKNO's ROE of -0.25%. Regarding short-term risk, TAK is less volatile compared to TKNO. This indicates lower risk in terms of short-term price fluctuations for TAK.Check TKNO's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 60B. In comparison, TLRY has a market cap of 461.9M. Regarding current trading prices, TAK is priced at $18.86 on the NYSE, while TLRY trades at $4.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 13.56, whereas TLRY's P/E ratio is -3.81. In terms of profitability, TAK's ROE is +0.02%, compared to TLRY's ROE of -0.08%. Regarding short-term risk, TAK is less volatile compared to TLRY. This indicates lower risk in terms of short-term price fluctuations for TAK.Check TLRY's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 60B. In comparison, CGC has a market cap of 397.5M. Regarding current trading prices, TAK is priced at $18.86 on the NYSE, while CGC trades at $0.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 13.56, whereas CGC's P/E ratio is -2.11. In terms of profitability, TAK's ROE is +0.02%, compared to CGC's ROE of -0.33%. Regarding short-term risk, TAK is less volatile compared to CGC. This indicates lower risk in terms of short-term price fluctuations for TAK.Check CGC's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 60B. In comparison, EBS has a market cap of 350.6M. Regarding current trading prices, TAK is priced at $18.86 on the NYSE, while EBS trades at $6.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 13.56, whereas EBS's P/E ratio is 4.72. In terms of profitability, TAK's ROE is +0.02%, compared to EBS's ROE of -0.36%. Regarding short-term risk, TAK is less volatile compared to EBS. This indicates lower risk in terms of short-term price fluctuations for TAK.Check EBS's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 60B. In comparison, ALIM has a market cap of 301.3M. Regarding current trading prices, TAK is priced at $18.86 on the NYSE, while ALIM trades at $5.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 13.56, whereas ALIM's P/E ratio is 5.28. In terms of profitability, TAK's ROE is +0.02%, compared to ALIM's ROE of -1.59%. Regarding short-term risk, TAK is more volatile compared to ALIM. This indicates higher risk in terms of short-term price fluctuations for TAK.Check ALIM's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 60B. In comparison, LNDC has a market cap of 263.6M. Regarding current trading prices, TAK is priced at $18.86 on the NYSE, while LNDC trades at $8.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 13.56, whereas LNDC's P/E ratio is -4.04. In terms of profitability, TAK's ROE is +0.02%, compared to LNDC's ROE of +6.44%. Regarding short-term risk, TAK is less volatile compared to LNDC. This indicates lower risk in terms of short-term price fluctuations for TAK.Check LNDC's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 60B. In comparison, ACB has a market cap of 254M. Regarding current trading prices, TAK is priced at $18.86 on the NYSE, while ACB trades at $4.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 13.56, whereas ACB's P/E ratio is -2.96. In terms of profitability, TAK's ROE is +0.02%, compared to ACB's ROE of -0.21%. Regarding short-term risk, TAK is less volatile compared to ACB. This indicates lower risk in terms of short-term price fluctuations for TAK.Check ACB's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 60B. In comparison, SIGA has a market cap of 247.4M. Regarding current trading prices, TAK is priced at $18.86 on the NYSE, while SIGA trades at $3.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 13.56, whereas SIGA's P/E ratio is 12.78. In terms of profitability, TAK's ROE is +0.02%, compared to SIGA's ROE of -0.02%. Regarding short-term risk, TAK is less volatile compared to SIGA. This indicates lower risk in terms of short-term price fluctuations for TAK.Check SIGA's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 60B. In comparison, TYHT has a market cap of 229.2M. Regarding current trading prices, TAK is priced at $18.86 on the NYSE, while TYHT trades at $11.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 13.56, whereas TYHT's P/E ratio is -1.61. In terms of profitability, TAK's ROE is +0.02%, compared to TYHT's ROE of -0.57%. Regarding short-term risk, TAK is less volatile compared to TYHT. This indicates lower risk in terms of short-term price fluctuations for TAK.Check TYHT's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 60B. In comparison, CRDL has a market cap of 197.1M. Regarding current trading prices, TAK is priced at $18.86 on the NYSE, while CRDL trades at $1.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 13.56, whereas CRDL's P/E ratio is -6.81. In terms of profitability, TAK's ROE is +0.02%, compared to CRDL's ROE of -1.94%. Regarding short-term risk, TAK is less volatile compared to CRDL. This indicates lower risk in terms of short-term price fluctuations for TAK.Check CRDL's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 60B. In comparison, ORGO has a market cap of 181.4M. Regarding current trading prices, TAK is priced at $18.86 on the NYSE, while ORGO trades at $1.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 13.56, whereas ORGO's P/E ratio is 47.00. In terms of profitability, TAK's ROE is +0.02%, compared to ORGO's ROE of -0.24%. Regarding short-term risk, TAK is less volatile compared to ORGO. This indicates lower risk in terms of short-term price fluctuations for TAK.Check ORGO's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 60B. In comparison, REPH has a market cap of 177.4M. Regarding current trading prices, TAK is priced at $18.86 on the NYSE, while REPH trades at $2.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 13.56, whereas REPH's P/E ratio is -8.04. In terms of profitability, TAK's ROE is +0.02%, compared to REPH's ROE of -0.22%. Regarding short-term risk, TAK is less volatile compared to REPH. This indicates lower risk in terms of short-term price fluctuations for TAK.Check REPH's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 60B. In comparison, DERM has a market cap of 169M. Regarding current trading prices, TAK is priced at $18.86 on the NYSE, while DERM trades at $6.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 13.56, whereas DERM's P/E ratio is -27.91. In terms of profitability, TAK's ROE is +0.02%, compared to DERM's ROE of -0.20%. Regarding short-term risk, TAK is less volatile compared to DERM. This indicates lower risk in terms of short-term price fluctuations for TAK.Check DERM's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 60B. In comparison, LFCR has a market cap of 157.5M. Regarding current trading prices, TAK is priced at $18.86 on the NYSE, while LFCR trades at $4.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 13.56, whereas LFCR's P/E ratio is -3.31. In terms of profitability, TAK's ROE is +0.02%, compared to LFCR's ROE of -3.77%. Regarding short-term risk, TAK is less volatile compared to LFCR. This indicates lower risk in terms of short-term price fluctuations for TAK.Check LFCR's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 60B. In comparison, THTX has a market cap of 155.9M. Regarding current trading prices, TAK is priced at $18.86 on the NYSE, while THTX trades at $3.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 13.56, whereas THTX's P/E ratio is -28.83. In terms of profitability, TAK's ROE is +0.02%, compared to THTX's ROE of +0.36%. Regarding short-term risk, TAK is less volatile compared to THTX. This indicates lower risk in terms of short-term price fluctuations for TAK.Check THTX's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 60B. In comparison, OGI has a market cap of 154.9M. Regarding current trading prices, TAK is priced at $18.86 on the NYSE, while OGI trades at $1.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 13.56, whereas OGI's P/E ratio is 2.47. In terms of profitability, TAK's ROE is +0.02%, compared to OGI's ROE of +0.21%. Regarding short-term risk, TAK is less volatile compared to OGI. This indicates lower risk in terms of short-term price fluctuations for TAK.Check OGI's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 60B. In comparison, ASRT has a market cap of 151.9M. Regarding current trading prices, TAK is priced at $18.86 on the NYSE, while ASRT trades at $23.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 13.56, whereas ASRT's P/E ratio is -7.10. In terms of profitability, TAK's ROE is +0.02%, compared to ASRT's ROE of -0.39%. Regarding short-term risk, TAK is more volatile compared to ASRT. This indicates higher risk in terms of short-term price fluctuations for TAK.Check ASRT's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 60B. In comparison, SCTL has a market cap of 116.1M. Regarding current trading prices, TAK is priced at $18.86 on the NYSE, while SCTL trades at $1.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 13.56, whereas SCTL's P/E ratio is -7.86. In terms of profitability, TAK's ROE is +0.02%, compared to SCTL's ROE of -0.22%. Regarding short-term risk, TAK is less volatile compared to SCTL. This indicates lower risk in terms of short-term price fluctuations for TAK.Check SCTL's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 60B. In comparison, CPIX has a market cap of 114M. Regarding current trading prices, TAK is priced at $18.86 on the NYSE, while CPIX trades at $7.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 13.56, whereas CPIX's P/E ratio is -19.02. In terms of profitability, TAK's ROE is +0.02%, compared to CPIX's ROE of -0.47%. Regarding short-term risk, TAK is less volatile compared to CPIX. This indicates lower risk in terms of short-term price fluctuations for TAK.Check CPIX's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 60B. In comparison, PROC has a market cap of 102.1M. Regarding current trading prices, TAK is priced at $18.86 on the NYSE, while PROC trades at $1.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 13.56, whereas PROC's P/E ratio is 1.53. In terms of profitability, TAK's ROE is +0.02%, compared to PROC's ROE of -2.22%. Regarding short-term risk, TAK is more volatile compared to PROC. This indicates higher risk in terms of short-term price fluctuations for TAK.Check PROC's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 60B. In comparison, OPTN has a market cap of 97.2M. Regarding current trading prices, TAK is priced at $18.86 on the NYSE, while OPTN trades at $9.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 13.56, whereas OPTN's P/E ratio is -4.42. In terms of profitability, TAK's ROE is +0.02%, compared to OPTN's ROE of +0.34%. Regarding short-term risk, TAK is more volatile compared to OPTN. This indicates higher risk in terms of short-term price fluctuations for TAK.Check OPTN's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 60B. In comparison, ZOM has a market cap of 95.3M. Regarding current trading prices, TAK is priced at $18.86 on the NYSE, while ZOM trades at $0.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 13.56, whereas ZOM's P/E ratio is -1.62. In terms of profitability, TAK's ROE is +0.02%, compared to ZOM's ROE of -0.17%. Regarding short-term risk, TAK is less volatile compared to ZOM. This indicates lower risk in terms of short-term price fluctuations for TAK.Check ZOM's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 60B. In comparison, BGM has a market cap of 91.4M. Regarding current trading prices, TAK is priced at $18.86 on the NYSE, while BGM trades at $0.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 13.56, whereas BGM's P/E ratio is -1.50. In terms of profitability, TAK's ROE is +0.02%, compared to BGM's ROE of -0.05%. Regarding short-term risk, TAK is less volatile compared to BGM. This indicates lower risk in terms of short-term price fluctuations for TAK.Check BGM's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 60B. In comparison, GRVI has a market cap of 88.9M. Regarding current trading prices, TAK is priced at $18.86 on the NYSE, while GRVI trades at $4.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 13.56, whereas GRVI's P/E ratio is 26.05. In terms of profitability, TAK's ROE is +0.02%, compared to GRVI's ROE of -4.51%. Regarding short-term risk, TAK is less volatile compared to GRVI. This indicates lower risk in terms of short-term price fluctuations for TAK.Check GRVI's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 60B. In comparison, ZYNE has a market cap of 70.1M. Regarding current trading prices, TAK is priced at $18.86 on the NYSE, while ZYNE trades at $1.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 13.56, whereas ZYNE's P/E ratio is -1.65. In terms of profitability, TAK's ROE is +0.02%, compared to ZYNE's ROE of -0.59%. Regarding short-term risk, TAK is less volatile compared to ZYNE. This indicates lower risk in terms of short-term price fluctuations for TAK.Check ZYNE's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 60B. In comparison, SSIC has a market cap of 66.7M. Regarding current trading prices, TAK is priced at $18.86 on the NYSE, while SSIC trades at $10.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 13.56, whereas SSIC's P/E ratio is 11.93. In terms of profitability, TAK's ROE is +0.02%, compared to SSIC's ROE of +0.00%. Regarding short-term risk, TAK is less volatile compared to SSIC. This indicates lower risk in terms of short-term price fluctuations for TAK.Check SSIC's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 60B. In comparison, ZYBT has a market cap of 63M. Regarding current trading prices, TAK is priced at $18.86 on the NYSE, while ZYBT trades at $1.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 13.56, whereas ZYBT's P/E ratio is -6.47. In terms of profitability, TAK's ROE is +0.02%, compared to ZYBT's ROE of -0.27%. Regarding short-term risk, TAK is less volatile compared to ZYBT. This indicates lower risk in terms of short-term price fluctuations for TAK.Check ZYBT's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 60B. In comparison, INCR has a market cap of 61.5M. Regarding current trading prices, TAK is priced at $18.86 on the NYSE, while INCR trades at $5.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 13.56, whereas INCR's P/E ratio is -4.98. In terms of profitability, TAK's ROE is +0.02%, compared to INCR's ROE of -0.09%. Regarding short-term risk, TAK is less volatile compared to INCR. This indicates lower risk in terms of short-term price fluctuations for TAK.Check INCR's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 60B. In comparison, VLNS has a market cap of 61.5M. Regarding current trading prices, TAK is priced at $18.86 on the NYSE, while VLNS trades at $0.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 13.56, whereas VLNS's P/E ratio is -1.03. In terms of profitability, TAK's ROE is +0.02%, compared to VLNS's ROE of N/A. Regarding short-term risk, TAK is less volatile compared to VLNS. This indicates lower risk in terms of short-term price fluctuations for TAK.Check VLNS's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 60B. In comparison, TLPH has a market cap of 61.2M. Regarding current trading prices, TAK is priced at $18.86 on the NYSE, while TLPH trades at $1.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 13.56, whereas TLPH's P/E ratio is -3.81. In terms of profitability, TAK's ROE is +0.02%, compared to TLPH's ROE of -0.87%. Regarding short-term risk, TAK is less volatile compared to TLPH. This indicates lower risk in terms of short-term price fluctuations for TAK.Check TLPH's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 60B. In comparison, DRRX has a market cap of 59.3M. Regarding current trading prices, TAK is priced at $18.86 on the NYSE, while DRRX trades at $1.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 13.56, whereas DRRX's P/E ratio is -4.44. In terms of profitability, TAK's ROE is +0.02%, compared to DRRX's ROE of -1.40%. Regarding short-term risk, TAK is more volatile compared to DRRX. This indicates higher risk in terms of short-term price fluctuations for TAK.Check DRRX's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 60B. In comparison, JUPW has a market cap of 49.3M. Regarding current trading prices, TAK is priced at $18.86 on the NYSE, while JUPW trades at $1.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 13.56, whereas JUPW's P/E ratio is -2.41. In terms of profitability, TAK's ROE is +0.02%, compared to JUPW's ROE of -3.04%. Regarding short-term risk, TAK is less volatile compared to JUPW. This indicates lower risk in terms of short-term price fluctuations for TAK.Check JUPW's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 60B. In comparison, QLI has a market cap of 38.7M. Regarding current trading prices, TAK is priced at $18.86 on the NYSE, while QLI trades at $5.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 13.56, whereas QLI's P/E ratio is -4.92. In terms of profitability, TAK's ROE is +0.02%, compared to QLI's ROE of -0.16%. Regarding short-term risk, TAK is more volatile compared to QLI. This indicates higher risk in terms of short-term price fluctuations for TAK.Check QLI's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 60B. In comparison, RMTI has a market cap of 33M. Regarding current trading prices, TAK is priced at $18.86 on the NYSE, while RMTI trades at $8.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 13.56, whereas RMTI's P/E ratio is -6.25. In terms of profitability, TAK's ROE is +0.02%, compared to RMTI's ROE of -0.14%. Regarding short-term risk, TAK is less volatile compared to RMTI. This indicates lower risk in terms of short-term price fluctuations for TAK.Check RMTI's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 60B. In comparison, HEXO has a market cap of 31.2M. Regarding current trading prices, TAK is priced at $18.86 on the NYSE, while HEXO trades at $0.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 13.56, whereas HEXO's P/E ratio is -0.26. In terms of profitability, TAK's ROE is +0.02%, compared to HEXO's ROE of -2.06%. Regarding short-term risk, TAK is less volatile compared to HEXO. This indicates lower risk in terms of short-term price fluctuations for TAK.Check HEXO's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 60B. In comparison, CPHI has a market cap of 30.6M. Regarding current trading prices, TAK is priced at $18.86 on the NYSE, while CPHI trades at $0.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 13.56, whereas CPHI's P/E ratio is -1.76. In terms of profitability, TAK's ROE is +0.02%, compared to CPHI's ROE of -0.17%. Regarding short-term risk, TAK is less volatile compared to CPHI. This indicates lower risk in terms of short-term price fluctuations for TAK.Check CPHI's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 60B. In comparison, AYTU has a market cap of 24.5M. Regarding current trading prices, TAK is priced at $18.86 on the NYSE, while AYTU trades at $2.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 13.56, whereas AYTU's P/E ratio is -0.50. In terms of profitability, TAK's ROE is +0.02%, compared to AYTU's ROE of -0.53%. Regarding short-term risk, TAK is less volatile compared to AYTU. This indicates lower risk in terms of short-term price fluctuations for TAK.Check AYTU's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 60B. In comparison, TXMD has a market cap of 23.7M. Regarding current trading prices, TAK is priced at $18.86 on the NYSE, while TXMD trades at $2.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 13.56, whereas TXMD's P/E ratio is 104.43. In terms of profitability, TAK's ROE is +0.02%, compared to TXMD's ROE of -0.01%. Regarding short-term risk, TAK is less volatile compared to TXMD. This indicates lower risk in terms of short-term price fluctuations for TAK.Check TXMD's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 60B. In comparison, CYTH has a market cap of 23.6M. Regarding current trading prices, TAK is priced at $18.86 on the NYSE, while CYTH trades at $0.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 13.56, whereas CYTH's P/E ratio is -0.80. In terms of profitability, TAK's ROE is +0.02%, compared to CYTH's ROE of -7.30%. Regarding short-term risk, TAK is more volatile compared to CYTH. This indicates higher risk in terms of short-term price fluctuations for TAK.Check CYTH's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 60B. In comparison, EVOK has a market cap of 18.9M. Regarding current trading prices, TAK is priced at $18.86 on the NYSE, while EVOK trades at $11.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 13.56, whereas EVOK's P/E ratio is -7.97. In terms of profitability, TAK's ROE is +0.02%, compared to EVOK's ROE of -0.89%. Regarding short-term risk, TAK is more volatile compared to EVOK. This indicates higher risk in terms of short-term price fluctuations for TAK.Check EVOK's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 60B. In comparison, OPTH has a market cap of 15.5M. Regarding current trading prices, TAK is priced at $18.86 on the NYSE, while OPTH trades at $4.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 13.56, whereas OPTH's P/E ratio is -3.35. In terms of profitability, TAK's ROE is +0.02%, compared to OPTH's ROE of -0.90%. Regarding short-term risk, TAK is less volatile compared to OPTH. This indicates lower risk in terms of short-term price fluctuations for TAK.Check OPTH's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 60B. In comparison, ACRX has a market cap of 14.6M. Regarding current trading prices, TAK is priced at $18.86 on the NYSE, while ACRX trades at $0.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 13.56, whereas ACRX's P/E ratio is -0.31. In terms of profitability, TAK's ROE is +0.02%, compared to ACRX's ROE of -0.87%. Regarding short-term risk, TAK is less volatile compared to ACRX. This indicates lower risk in terms of short-term price fluctuations for TAK.Check ACRX's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 60B. In comparison, CABR has a market cap of 10.8M. Regarding current trading prices, TAK is priced at $18.86 on the NYSE, while CABR trades at $1.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 13.56, whereas CABR's P/E ratio is -1.53. In terms of profitability, TAK's ROE is +0.02%, compared to CABR's ROE of -3.86%. Regarding short-term risk, TAK is less volatile compared to CABR. This indicates lower risk in terms of short-term price fluctuations for TAK.Check CABR's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 60B. In comparison, AGRX has a market cap of 10.4M. Regarding current trading prices, TAK is priced at $18.86 on the NYSE, while AGRX trades at $1.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 13.56, whereas AGRX's P/E ratio is -0.89. In terms of profitability, TAK's ROE is +0.02%, compared to AGRX's ROE of +1.32%. Regarding short-term risk, TAK is less volatile compared to AGRX. This indicates lower risk in terms of short-term price fluctuations for TAK.Check AGRX's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 60B. In comparison, NLTX has a market cap of 8.2M. Regarding current trading prices, TAK is priced at $18.86 on the NYSE, while NLTX trades at $3.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 13.56, whereas NLTX's P/E ratio is -0.28. In terms of profitability, TAK's ROE is +0.02%, compared to NLTX's ROE of -0.45%. Regarding short-term risk, TAK is less volatile compared to NLTX. This indicates lower risk in terms of short-term price fluctuations for TAK.Check NLTX's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 60B. In comparison, LCI has a market cap of 7.4M. Regarding current trading prices, TAK is priced at $18.86 on the NYSE, while LCI trades at $0.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 13.56, whereas LCI's P/E ratio is -0.04. In terms of profitability, TAK's ROE is +0.02%, compared to LCI's ROE of +1.66%. Regarding short-term risk, TAK is less volatile compared to LCI. This indicates lower risk in terms of short-term price fluctuations for TAK.Check LCI's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 60B. In comparison, ADMP has a market cap of 7.3M. Regarding current trading prices, TAK is priced at $18.86 on the NYSE, while ADMP trades at $0.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 13.56, whereas ADMP's P/E ratio is -0.08. In terms of profitability, TAK's ROE is +0.02%, compared to ADMP's ROE of -2.09%. Regarding short-term risk, TAK is less volatile compared to ADMP. This indicates lower risk in terms of short-term price fluctuations for TAK.Check ADMP's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 60B. In comparison, GELS has a market cap of 5M. Regarding current trading prices, TAK is priced at $18.86 on the NYSE, while GELS trades at $0.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 13.56, whereas GELS's P/E ratio is -1.09. In terms of profitability, TAK's ROE is +0.02%, compared to GELS's ROE of -0.25%. Regarding short-term risk, TAK is less volatile compared to GELS. This indicates lower risk in terms of short-term price fluctuations for TAK.Check GELS's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 60B. In comparison, YCBD has a market cap of 4.8M. Regarding current trading prices, TAK is priced at $18.86 on the NYSE, while YCBD trades at $0.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 13.56, whereas YCBD's P/E ratio is -1.13. In terms of profitability, TAK's ROE is +0.02%, compared to YCBD's ROE of -0.34%. Regarding short-term risk, TAK is less volatile compared to YCBD. This indicates lower risk in terms of short-term price fluctuations for TAK.Check YCBD's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 60B. In comparison, MNK has a market cap of 4.5M. Regarding current trading prices, TAK is priced at $18.86 on the NYSE, while MNK trades at $0.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 13.56, whereas MNK's P/E ratio is -0.44. In terms of profitability, TAK's ROE is +0.02%, compared to MNK's ROE of -0.36%. Regarding short-term risk, TAK is less volatile compared to MNK. This indicates lower risk in terms of short-term price fluctuations for TAK.Check MNK's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 60B. In comparison, FLGC has a market cap of 4.2M. Regarding current trading prices, TAK is priced at $18.86 on the NYSE, while FLGC trades at $7.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 13.56, whereas FLGC's P/E ratio is -0.19. In terms of profitability, TAK's ROE is +0.02%, compared to FLGC's ROE of -3.03%. Regarding short-term risk, TAK is less volatile compared to FLGC. This indicates lower risk in terms of short-term price fluctuations for TAK.Check FLGC's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 60B. In comparison, UPC has a market cap of 2.9M. Regarding current trading prices, TAK is priced at $18.86 on the NYSE, while UPC trades at $4.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 13.56, whereas UPC's P/E ratio is -0.57. In terms of profitability, TAK's ROE is +0.02%, compared to UPC's ROE of -0.03%. Regarding short-term risk, TAK is less volatile compared to UPC. This indicates lower risk in terms of short-term price fluctuations for TAK.Check UPC's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 60B. In comparison, PLXP has a market cap of 2.5M. Regarding current trading prices, TAK is priced at $18.86 on the NYSE, while PLXP trades at $0.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 13.56, whereas PLXP's P/E ratio is -0.22. In terms of profitability, TAK's ROE is +0.02%, compared to PLXP's ROE of -1.66%. Regarding short-term risk, TAK is less volatile compared to PLXP. This indicates lower risk in terms of short-term price fluctuations for TAK.Check PLXP's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 60B. In comparison, INM has a market cap of 2.5M. Regarding current trading prices, TAK is priced at $18.86 on the NYSE, while INM trades at $1.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 13.56, whereas INM's P/E ratio is -0.25. In terms of profitability, TAK's ROE is +0.02%, compared to INM's ROE of -1.35%. Regarding short-term risk, TAK is less volatile compared to INM. This indicates lower risk in terms of short-term price fluctuations for TAK.Check INM's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 60B. In comparison, SHPH has a market cap of 2.3M. Regarding current trading prices, TAK is priced at $18.86 on the NYSE, while SHPH trades at $4.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 13.56, whereas SHPH's P/E ratio is -0.19. In terms of profitability, TAK's ROE is +0.02%, compared to SHPH's ROE of -1.57%. Regarding short-term risk, TAK is less volatile compared to SHPH. This indicates lower risk in terms of short-term price fluctuations for TAK.Check SHPH's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 60B. In comparison, ATNX has a market cap of 2.3M. Regarding current trading prices, TAK is priced at $18.86 on the NYSE, while ATNX trades at $0.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 13.56, whereas ATNX's P/E ratio is -0.02. In terms of profitability, TAK's ROE is +0.02%, compared to ATNX's ROE of +0.22%. Regarding short-term risk, TAK is more volatile compared to ATNX. This indicates higher risk in terms of short-term price fluctuations for TAK.Check ATNX's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 60B. In comparison, SNOA has a market cap of 2.1M. Regarding current trading prices, TAK is priced at $18.86 on the NYSE, while SNOA trades at $1.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 13.56, whereas SNOA's P/E ratio is -1.14. In terms of profitability, TAK's ROE is +0.02%, compared to SNOA's ROE of -0.54%. Regarding short-term risk, TAK is less volatile compared to SNOA. This indicates lower risk in terms of short-term price fluctuations for TAK.Check SNOA's competition here

Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TAK stands at 60B. In comparison, SBFM has a market cap of 2M. Regarding current trading prices, TAK is priced at $18.86 on the NYSE, while SBFM trades at $0.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TAK currently has a P/E ratio of 13.56, whereas SBFM's P/E ratio is -0.14. In terms of profitability, TAK's ROE is +0.02%, compared to SBFM's ROE of -0.24%. Regarding short-term risk, TAK is less volatile compared to SBFM. This indicates lower risk in terms of short-term price fluctuations for TAK.Check SBFM's competition here